

## PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT										
NATURE OF CONVEYANCE:	ASSIGNMENT										
CONVEYING PARTY DATA											
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Moshe REHAVI</td> <td>10/28/2012</td> </tr> <tr> <td>David GURWITZ</td> <td>10/29/2012</td> </tr> </tbody> </table>		Name	Execution Date	Moshe REHAVI	10/28/2012	David GURWITZ	10/29/2012				
Name	Execution Date										
Moshe REHAVI	10/28/2012										
David GURWITZ	10/29/2012										
RECEIVING PARTY DATA											
<table border="1"> <tr> <td>Name:</td> <td>Ramot at Tel-Aviv University Ltd.</td> </tr> <tr> <td>Street Address:</td> <td>P.O. Box 39296</td> </tr> <tr> <td>City:</td> <td>Tel-Aviv</td> </tr> <tr> <td>State/Country:</td> <td>ISRAEL</td> </tr> <tr> <td>Postal Code:</td> <td>6139201</td> </tr> </table>		Name:	Ramot at Tel-Aviv University Ltd.	Street Address:	P.O. Box 39296	City:	Tel-Aviv	State/Country:	ISRAEL	Postal Code:	6139201
Name:	Ramot at Tel-Aviv University Ltd.										
Street Address:	P.O. Box 39296										
City:	Tel-Aviv										
State/Country:	ISRAEL										
Postal Code:	6139201										
PROPERTY NUMBERS Total: 1											
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>13757944</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	13757944						
Property Type	Number										
Application Number:	13757944										
CORRESPONDENCE DATA											
<p>Fax Number: 7187668494  <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i></p> <p>Phone: 7182468482        Email: jason@ipatent.co.il        Correspondent Name: Jason Rosenblum, c/o Martin Moynihan        Address Line 1: P.O. Box 16446        Address Line 2: PRTSI, Inc.        Address Line 4: Arlington, VIRGINIA 22215</p>											
ATTORNEY DOCKET NUMBER:	55016										
NAME OF SUBMITTER:	Jason H. Rosenblum										
<p>Total Attachments: 1        source=55016 Executed Assignment#page1.tif</p>											

CH \$40.00 13757944

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned:

**Moshe REHAVI**  
4 Boaz Street  
47402 Ramat-HaSharon  
Israel

**David GURWITZ**  
4 HaYedidut Street  
45297 Hod-HaSharon  
Israel

hereby sell(s), assign(s) and transfer(s) to:

**Ramot at Tel-Aviv University Ltd.**  
P.O. Box 39296  
61392 Tel-Aviv  
Israel

(hereinafter called the "Assignee"), its successors, assigns, nominees or other legal representatives, the undersigned's entire rights, title and interest in and to the invention titled:

**NOVEL SEROTONIN REUPTAKE INHIBITORS AS DRUGS HAVING  
PERIPHERAL-SYSTEM-RESTRICTED ACTIVITY**

described and claimed in the following Patent Application:

**Patent Application to be filed in the USA,  
executed the same date as this assignment,  
and identified as Attorney Docket No. 55016**

and in and to said Patent Application, and all original and reissued Patents granted therefore, and all divisions and continuations thereof, any corresponding PCT Patent Application and the National Phases thereof, including the right to apply and obtain Patents in all other countries, the priority rights under International Conventions, and the Letters Patent which may be granted thereon:

covenant that the undersigned have (has) the full right to convey the entire interest therein assigned;

authorize(s) and request(s) the Registrar of Patents, and any Official of any country whose duty it is to issue Patents on applications as aforesaid, to issue the said Letters Patent to the said Assignee;

and agree(s) to sign all lawful papers, make all rightful oaths, do all lawful acts requisite for such Patent Applications, and do everything possible to aid said Assignee to apply for, obtain and enforce Patent protection for said invention.

  
\_\_\_\_\_  
Moshe REHAVI

Date: 28.10.12

  
\_\_\_\_\_  
David GURWITZ

Date: Oct 29, 2012